References
Tang Q, Holland-Letz T, Slynko A, Cuk K, Marme F, Schott S, Heil J, Qu B, Golatta M, Bewerunge-Hudler M, Sutter C, Surowy H, Wappenschmidt B, Schmutzler R, Hoth M, Bugert P, Bartram CR, Sohn C, Schneeweiss A, Yang R, Burwinkel B (2016) DNA methylation array analysis identifies breast cancer associated - RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. Oncotarget. doi:10.18632/oncotarget.11640
Severi G, Southey MC, English, Jung CH, Lonie A, McLean C, Tsimiklis H, Hopper JL, Giles GG, Baglietto L (2014) Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat 148:665–673. doi:10.1007/s10549-014-3209-y
Dugué PA, English DR, MacInnis RJ, Jung CH, Bassett JK, FitzGerald LM, Wong EM, Joo JE, Hopper JL, Southey MC, Giles GG, Milne RL (2016) Reliability of DNA methylation measures from dried blood spots and mononuclear cells using the HumanMethylation450 k BeadArray. Sci Rep. 6:30317. doi:10.1038/srep30317
Funding
Melissa C. Southey was supported by National Health and Medical Research Council (Grant Nos.: APP1011618, APP1061177).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Dugué, PA., Milne, R.L. & Southey, M.C. A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer. Breast Cancer Res Treat 161, 181–183 (2017). https://doi.org/10.1007/s10549-016-4032-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-016-4032-4